Sanofi to buy Bioverativ, Biogen's hemophilia spinout, for $11.6B
January 22, 2018 at 07:06 AM EST
The deal is one of the largest struck by Sanofi in years, and marks its latest aggressive push into the market for hemophilia drugs.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|